Back to Search Start Over

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors :
Loibl, S
Majewski, I
Guarneri, V
Nekljudova, V
Holmes, E
Bria, E
Denkert, C
Schem, C
Sotiriou, C
Loi, S
Source :
Annals of Oncology. Oct2018, Vol. 29 Issue 10, p2151-2151. 1p.
Publication Year :
2018

Details

Language :
English
ISSN :
09237534
Volume :
29
Issue :
10
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
132935377
Full Text :
https://doi.org/10.1093/annonc/mdx803